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contaminated with pathogens, and may influence cellular assays, 
can be replaced with human serum or with chemically defined me-
dium. Different formulations of chemically defined media should 
be tried and cells may need to be adapted to a chemically defined 
medium by a gradual adaptation strategy. 
Alison Gray (Afability, UK) stated that millions of animals 
are still used worldwide to develop antibodies although cruel-
ty-free methods were developed 20 years ago. The phage-dis-
play methodology generates an enormous antibody repertoire 
with a huge molecular diversity at the antibody binding site from 
natural or synthetic gene fragments. Clonal selection takes place 
in bacteria. EU-level guidance and recommendations could help 
to promote the use of animal-free instead of animal-derived an-
tibodies. 
Jan van der Valk (3Rs Centre Utrecht, The Netherlands) spoke 
on fetal bovine serum, which has been a universal, little questioned 
cell culture supplement for decades. Replacement of the use of 
FBS is gaining traction as OECD and FDA are now discouraging 
its use and recommending the use of chemically defined media. 
The database “FCS-free” informs on suitable chemically defined 
media for cells and contains relevant confirmatory data.
Carol Treasure (XCellR8, Cheshire, UK) explained that 
XCellR8 has established animal product-free methods that are ac-
cepted by OECD for testing skin and eye irritation and corrosion 
by replacing all animal-derived products. There are ethical issues 
around the use of human-derived reagents in some countries and 
human serum is far more expensive than FBS, however these re-
agents make up only a small part of the overall testing costs. In 
her experience, leading with the science and understanding the 
practical needs of industry is essential to winning companies over 
to using cruelty-free methods.
Gill Langley (Humane Society International) closed the con-
ference by summing up the key themes as being technology, mul-
tidisciplinarity, interfaces, funding, and positive communication 
and by thanking the speakers and audience.
sva
identify relevant modes of action that can be used to design target-
ed testing approaches based on, among others, microphysiological 
systems and computational models. 
The ensuing round table discussion with the speakers included 
discussion on translating research results to models that compa-
nies can use, validating new approach methods based on reliabili-
ty and relevance instead of by comparing them to animal tests, and 
the potential role of AOPs in reshaping the validation process and 
current challenges of organs-on-a-chip technology.
The book “Animal Experimentation: Working Towards a Para- 
digm Change” was introduced by Kathrin Herrmann (CAAT, 
Johns Hopkins Bloomberg School of Public Health, Baltimore, 
MD, USA). While animal experiments are hailed to be indispens-
able to progress in human healthcare, less than 12% of drugs en-
tering human trials after preclinical testing gain market approval. 
Studies also have reported that 50-90% of preclinical studies are 
not reproducible. The book, which is aimed at both scientists and 
laypersons, reviews the current use of animals in science and pres-
ents approaches towards achieving change.
After the break-out sessions, TJ Bozana (ToxTrack, Inc., Bal-
timore, MD, USA) explained how cheminformatics technologies 
are increasing access to big data, i.e., fusing and analyzing large 
databases. UL Cheminformatics is a suite of predictive models 
for nine health hazards based on read-across structure activity 
relationships (RASAR) developed from machine learning ap-
proaches. The analysis of large databases on toxicological data 
showed that six animal toxicity tests have an average sensitivity 
of 70%, while the RASAR technology reaches an average sen-
sitivity of 89% across the same end-points with a coverage of 
100% of all chemicals.
Bianca Marigliani (INMETRO, Federal University of São 
Paulo, Brazil) called for abstaining from using animal-derived 
products, such as fetal bovine serum, trypsin, collagen, etc. for 
nonanimal methods as they cannot be designated as cruelty-free 
otherwise. Fetal bovine serum (FBS), which is produced from 
the blood of fetuses upon slaughter of pregnant cows, has an 
ill-defined composition, may differ from batch to batch, may be 
pronounced in the more complex 3D cell models, which are 
less accessible to optical imaging. Therefore, improvements in 
imaging, data acquisition, and analysis tools including chemical 
sensing are necessary for broad adoption of 3D cell cultures for 
screening. Furthermore, regulatory authorities have yet to accept 
data obtained from 3D cell models as a surrogate or at least as a 
partial substitution for pre-clinical animal testing.
The Competence Centre TEDD (Tissue Engineering for 
Drug Development and Substance Testing) is a collaborative 
innovation platform dedicated to 3D cell culture technology and 
Microfabrication techniques and tissue engineering have enabled 
the development of a wide range of 3D cell culture technologies, 
including multicellular spheroids, organoids, scaffolds, hydro-
gels, organ-on-a-chip systems, and 3D bioprinting, each with its 
advantages and disadvantages. 3D models have been penetrating 
the early drug discovery process, starting from disease modelling 
to target identification, validation and screening, lead selection, 
efficacy, and safety assessment. 
However, while challenges remain in the standardization of 
culture and assay protocols in 2D systems, this is even more 
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reduce the failure rate and facilitate decision making in the drug 
discovery and development pipeline. Dr Ferrer illustrated the use 
of biofabrication techniques at NCATS, and the development of 
assay readouts in 3D tissues with the aim of creating a catalogue 
of normal and disease models for toxicity and drug efficacy 
screening. He also discussed the importance of harmonizing the 
validation of these models based on throughput capacity and 
physiological complexity as a requirement to establish their true 
translational capacity (Kelm et al., 2018). 
Prof. Stefan Przyborski from Durham University and CSO 
of Reprocell Europe Ltd, UK, presented scaffold-based technol-
ogy for generation of in vivo-like tissue models called Alvetex. 
Cells grown in Alvetex possess a natural tissue-like structure 
enabling them to function in a more physiologically relevant 
manner. The scaffold comprises a highly porous polystyrene ma-
terial, engineered into a membrane in multi-welled plates, and 
well inserts for use with conventional culture plastic ware and 
medium perfusion systems (Knight and Przyborski, 2015). He 
showed examples of application in a neuron-glial co-culture to 
study neurite outgrowth interacting with astrocytes in the glial 
scar found in spinal cord injury, and models of a sub-mucosa and 
skin (Fig. 1). Prof. Przyborski concluded with the statement that 
these models, which recreate the structure of tissues, promise to 
become a valuable research tool for use in drug discovery. 
Dr Dieter Ulrich (CSEM, Landquart, Switzerland) presented 
an engineering approach for monitoring of cell culture condi-
tions. In the last decades, traditional bioprocesses in large-scale 
steel bioreactors have shifted to disposable cell culture platforms 
coupled with individualized cell therapy or drug screening with 
body-on-a-chip systems. This trend requires innovative stan-
dardized analytical solutions to control the bioprocesses, par-
ticularly for small-scale bioprocesses. CSEM is working on the 
development of an at-line cell culture monitoring platform used 
with, e.g., microbial and mammalian bioprocesses, which uses 
organ-like tissue models for drug development, substance test-
ing, and personalized and regenerative medicine. TEDD aims 
to accelerate science application and technology development 
in industrial R&D, to validate in vitro models, and to highlight 
Switzerland as an international biomedical industry location. 
One of TEDD’s core goals is the implementation of the 3R (Re-
placement, Reduction, and Refinement) principles through the 
introduction of validated technologies as an alternative to animal 
testing. The TEDD community comprises more than 100 Swiss 
and international members from academia, clinical medicine, 
and industry. 
The TEDD Annual Meeting 2018 was held at the Zurich Uni-
versity of Applied Sciences (ZHAW) in Wädenswil, Switzerland 
on October 24-25. It brought together experts from diverse fields 
with a shared interest in advanced 3D models. The idea was to 
stimulate exchange and collaborations between 3D cell model 
developers and experts in advanced analysis methods: micros-
copy, sensors, data modelling, and high-throughput screening. 
Sixteen industrial exhibitors were present during the extended 
networking lunch break at the ZHAW Greenhouse. 
Preceding the main symposium, TEDD hosted a Think Tank 
Meeting on “Advanced in vitro model validation. Segmentation 
and harmonization throughout the drug discovery chain” in collab-
oration with PreComb Therapeutics. Key opinion leaders included 
Dr Marc Ferrer from the National Institutes of Health/National 
Center for Advancing Translational Sciences (NIH/NCATS), 
USA; Prof. Sue Gibbs from Amsterdam University Medical 
Centre, The Netherlands; Dr Patrick Guye from InSphero, and Dr 
Kasper Renggli from Department of Biosystems Science and En-
gineering, ETH, Switzerland. Experts discussed how to accelerate 
the use of advanced in vitro models and their incorporation into 
drug discovery and development processes. Two critical aspects 
of the discussion round were segmentation according to 3D mod-
els’ scalability to define validation groups, and harmonisation for 
efficacy and safety testing that would enable direct comparison 
and assess their translational value. The meeting leaders, Prof. Mi-
chael Raghunath and Dr Jens Kelm concluded the meeting with 
a projection of further steps and actions needed to facilitate the 
validation of cell culture models.
Prof. Michael Raghunath, the director of TEDD, opened the 
main symposium on October 25, 2018. He presented the net-
work’s goals, structure, activities, and achievements in 2018 to 
close to 150 TEDD members and collaborators. 
Dr Marc Ferrer from NIH/NCATS kicked the meeting off 
with a keynote talk on integrating 3D cell models into the drug 
development pipeline. In the last decades, the clinical failure rate 
of drugs from submission to drug approval has remained close 
to 90% despite significant scientific and technological advances 
in the fields of biomedicine and biopharmaceutical R&D. Re-
sults of current in vitro and in vivo toxicity and efficacy assays 
still appear to translate poorly into clinical outcome in humans. 
To improve in vitro physiology, 3D tissue models are being de-
veloped for pre-clinical drug testing but their predictive ability 
must be validated systematically. Ongoing and future studies 
with thoroughly validated tissues of higher cellular complexity 
should generate evidence as to how predictive 3D tissue models 
are of drug activity in humans, and how much they can help to 
Fig. 1: Skin model developed with the Alvetex platform
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(LSFM). Experiments on 3D biological specimens such as cysts, 
organoids, spheroids, embryonic bodies, tissue sections, and small 
model organisms require the development of new microscopes 
and image processing tools/software that are capable of handling 
millions of large-scale images for various applications. Classical 
fluorescence microscopy provides high contrast but has several 
disadvantages such as photobleaching of fluorophores and mini-
mal optical sectioning capability. One of the very few instruments 
that promises dynamic 3D imaging and addresses these disad-
vantages of traditional tools, is light sheet-based fluorescence 
microscopy (LSFM). Particular benefits of LSFM are a good axial 
resolution, imaging along multiple directions, deeper tissue pene-
tration, high signal-to-noise ratio, unrestricted compatibility with 
fluorescent dyes and proteins, reduced fluorophore-bleaching and 
phototoxicity at almost any scale, millions of pixels recorded in 
parallel, and excellent specimen viability.
The talk of Dr Andreas Meyer from FGen, Basel, Switzer-
land was on a technology platform for high throughput screen-
ing of 3D cell cultures using a flow cytometer. The technique 
addresses the analysis of large cell libraries or complex cell 
populations, an essential process in pharmaceutical discovery. 
Nanoliter-reactors (NLRs) encapsulate single cells that pro-
liferate to clonal spheroids or 3D cell clusters (Fig. 3). Flow 
cytometry is applied to analyze NLRs based on fluorescent-
ly-labelled surface markers to select spheroids. The technology 
platform is intended to be used for the isolation of specific 
cancer cells from complex cell mixtures such as biopsies for 
the identification of drug targets by high throughput screening 
of cell libraries. A mesothelioma model system was presented 
as proof of concept. Single cells showed high survival and pro-
liferation rates when encapsulated in NLRs. Flow cytometry 
readily identified and isolated spheroids. Cultivation of the 
mesothelioma cell line in NLRs with different matrix stiffness 
showed differential growth behavior, spheroid size, and expres-
sion of specific cancer markers.
low-cost disposable sensors as sensing units. Electrochemical 
detection of metabolites and ions occurs via an at-line automated 
sampling platform in quasi-real time. The control of bioprocess-
es is crucial in order to achieve optimized production, product 
folding and secretion from fully viable cells, which results in 
enhanced product quality and higher product titers. Dr Ulrich 
concluded that CSEM’s small-scale analytical platform could be 
a step towards an inexpensive monitoring technology fulfilling 
future industrial needs.
The next two talks addressed microscopy techniques. Dr 
Martin Rausch from Novartis presented a 3D cell culture-based 
compound screening technique based on a 2-photon microscope 
with fully integrated multi-channel microfluidic perfusion. Until 
recently, live cell imaging in 3D cell cultures with conventional 
microscopes or high-content imaging systems was challenging. 
Limitations include high phototoxicity, insufficient axial resolu-
tion, a need for specialized sample handling devices, and lack of 
tools for precise compound administration. Novartis developed 
a new imaging setup based on an inverted multi-photon micro-
scope, with a fully water-immersed high-NA (numerical aper-
ture) long working distance lens and compound administration 
by microfluidic perfusion. It allows generation of high-resolu-
tion image stacks from 3D cell cultures for medium-throughput 
compound screening assays in standard 24-384 well plates over 
many days (Fig. 2). Novartis successfully applied the system to 
image tumor and liver spheroids, tissue explants from muscle, 
skin and gut, as well as different types of co-cultures.
Prof. Dr Ernst Stelzer from Goethe University, Frankfurt, 
Germany introduced light sheet-based fluorescence microscopy 
Fig. 2: 3D 2-photon scan of an organoid 
The data is part of a multi-day live cell imaging experiment, 
monitoring the intensity and distribution of a green and red 
fluorescent protein in the cells.
Fig. 3: Microscopic picture of nanoliter-reactors (NLRs) 
containing clonal spheroids grown from single encapsulated 
cells of the mesothelioma cell line
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by incorporating more cell types into different models. While 
the simplest skin models consist of only differentiated stratified 
keratinocyte layers, full thickness models incorporate a dermal 
compartment with fibroblasts and additional cell types such as 
immune cells. The major challenge is now to develop optimal 
biomarker readouts (proteomics, transcriptomics and metabolo-
mics) suitable for the throughput of the different skin models, ei-
ther extracted from tissue or collected from the culture medium. 
However, while many technologies are available for small-scale 
discovery experiments, validated panels of biomarkers will be 
required for robust and cost-effective screening purposes. Prof. 
Gibbs pointed out that a compromise is required, which enables 
full exploitation of the advanced skin models’ physiological 
potential with available screening procedures that comply with 
future regulatory acceptance. 
Prof. Raghunath closed the Annual Meeting by announcing 
upcoming events and activities of TEDD in 2019 (3D cell cul-
ture SMI London, TEDD symposia at TERMIS-EU). The next 
TEDD Annual Meeting scheduled for October 24, 2019 promis-
es again a vibrant atmosphere, a top-quality scientific program, 
and a mix of participants from academia, industry and clinics.
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Dr Sylke Hoehnel, CEO of SUN Bioscience, Lausanne, Swit-
zerland took us on a tour of bioscience’s path from a working 
prototype to an industrial-scale product of complex 3D tissue 
models. Patient-specific, stem cell-derived organoids allow 
testing for the final efficacy of treatments rather than relying on 
predictions based on incomplete biomarker sets. However, or-
ganoids are still a research tool, and are produced manually, with 
high variability and high associated costs. SUN Bioscience has 
developed Gri3D®, a universal organoid culture platform that al-
lows standardization of organoids for their time- and cost-effec-
tive use in pharmaceutical screening and clinical diagnostics. A 
translational pilot study using the platform is currently underway 
that aims at understanding treatment response variability using 
intestinal organoids grown from cystic fibrosis patients.
Dr Carmel B. Nanthakumar, Fibrosis Disease Biology and 
Imaging, GlaxoSmithKline, UK, presented in vitro platforms 
for anti-fibrotic drug development. Matrix remodeling is a crit-
ical component of tissue fibrosis, and excessive deposition of a 
collagen-rich extracellular matrix (ECM) leads to loss of tissue 
compliance and, ultimately, organ failure. At the cellular level, 
the myofibroblast is central to the pathogenesis of fibrosis irre-
spective of tissue origin. Upon activation, this cell type drives 
remodeling by coupling tension and ECM synthesis. Existing 
models of experimentally induced lung fibrosis currently fail to 
recapitulate clinical features. Patient tissue- and disease-derived 
primary cells offer several advantages to pre-clinical fibrosis 
drug discovery and may be used to progress intervention strate-
gies that block myofibroblast activation and arrest ECM synthe-
sis. A cornerstone of establishing these complex phenotypic and 
physiologically relevant models was the early adoption of mac-
romolecular crowding, a technology spearheaded by Michael 
Raghunath to facilitate in vitro ECM deposition. The current in 
vitro models at GSK are used to study clinical biomarkers in cell 
and tissue preparations intending to bridge pre-clinical findings 
to clinical development in patients. 
The last presentation, given by Prof. Sue Gibbs from Amster-
dam University Medical Centre, highlighted how in vitro skin 
can be used as a screening tool. Understanding the healthy and 
diseased state of skin is essential in many areas of basic and ap-
plied research. The field of skin tissue engineering is advancing 
